{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:20:25Z","timestamp":1792783225406,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2026-25510921"],"award-info":[{"award-number":["RS-2026-25510921"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2025-22852971"],"award-info":[{"award-number":["RS-2025-22852971"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Science and ICT","award":["RS-2025-02311629"],"award-info":[{"award-number":["RS-2025-02311629"]}],"id":[{"id":"https:\/\/ror.org\/01wpjm123","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2026-25504267"],"award-info":[{"award-number":["RS-2026-25504267"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s11523-026-01252-x","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:28:31Z","timestamp":1788244111000},"page":"761-773","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Regorafenib as Second-Line Versus Later-Line Therapy in Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study with Exploratory Analysis of Prior Immune Checkpoint Inhibitor Exposure"],"prefix":"10.1007","volume":"21","author":[{"given":"Kwon Yong","family":"Tak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Sun","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaejun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyeungmo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahlim","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Won","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon Kyu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heechul","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do Seon","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myeong Jun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Hyun","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"UIm","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon Woo","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Won","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si Hyun","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3242-8883","authenticated-orcid":false,"given":"Hae Lim","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5780-9607","authenticated-orcid":false,"given":"Pil Soo","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"issue":"2","key":"1252_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2024.102446","volume":"15","author":"SP Singh","year":"2025","unstructured":"Singh SP, Madke T, Chand P. Global epidemiology of hepatocellular carcinoma. J Clin Exp Hepatol. 2025;15(2):102446. https:\/\/doi.org\/10.1016\/j.jceh.2024.102446.","journal-title":"J Clin Exp Hepatol"},{"issue":"4","key":"1252_CR2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378\u201390. https:\/\/doi.org\/10.1056\/NEJMoa0708857.","journal-title":"N Engl J Med"},{"issue":"10064","key":"1252_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P, Granito A, Huang Y-H, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(16)32453-9.","journal-title":"Lancet"},{"issue":"10126","key":"1252_CR4","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(18)30207-1.","journal-title":"Lancet"},{"issue":"1","key":"1252_CR5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","volume":"379","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa GK, Meyer T, Cheng A-L, El-Khoueiry AB, Rimassa L, Ryoo B-Y, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54\u201363. https:\/\/doi.org\/10.1056\/NEJMoa1717002.","journal-title":"N Engl J Med"},{"issue":"2","key":"1252_CR6","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","volume":"20","author":"AX Zhu","year":"2019","unstructured":"Zhu AX, Kang Y-K, Yen C-J, Finn RS, Galle PR, Llovet JM, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282\u201396. https:\/\/doi.org\/10.1016\/S1470-2045(18)30937-9.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1252_CR7","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3350\/cmh.2022.0421","volume":"29","author":"T-H Su","year":"2023","unstructured":"Su T-H, Wu C-H, Liu T-H, Ho C-M, Liu C-J. Clinical practice guidelines and real-life practice in hepatocellular carcinoma: a Taiwan perspective. Clin Mol Hepatol. 2023;29(2):230\u201341. https:\/\/doi.org\/10.3350\/cmh.2022.0421.","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"1252_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.17998\/jlc.2025.02.03","volume":"25","author":"H Shin","year":"2025","unstructured":"Shin H, Yu SJ. A concise review of updated global guidelines for the management of hepatocellular carcinoma: 2017-2024. J Liver Cancer. 2025;25(1):19\u201330. https:\/\/doi.org\/10.17998\/jlc.2025.02.03.","journal-title":"J Liver Cancer"},{"issue":"20","key":"1252_CR9","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905. https:\/\/doi.org\/10.1056\/NEJMoa1915745.","journal-title":"N Engl J Med"},{"issue":"1","key":"1252_CR10","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/HEP.0000000000001269","volume":"82","author":"TH Taddei","year":"2025","unstructured":"Taddei TH, Brown DB, Yarchoan M, Mendiratta-Lala M, Llovet JM. Critical update: AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2025;82(1):272\u20134. https:\/\/doi.org\/10.1097\/HEP.0000000000001269.","journal-title":"Hepatology"},{"issue":"2","key":"1252_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","author":"B Sangro","year":"2025","unstructured":"European Association for the Study of the Liver, Sangro B, Argemi J, Ronot M, Paradis V, Meyer T, et al. EASL clinical practice guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82(2):315\u201374. https:\/\/doi.org\/10.1016\/j.jhep.2024.08.028.","journal-title":"J Hepatol"},{"issue":"2","key":"1252_CR12","doi-asserted-by":"publisher","first-page":"178","DOI":"10.17998\/jlc.2025.06.13","volume":"25","author":"HS Chun","year":"2025","unstructured":"Chun HS, Lee M, Kim TH. Evolving roles of systemic therapy in hepatocellular carcinoma: neoadjuvant and adjuvant strategies. J Liver Cancer. 2025;25(2):178\u201386. https:\/\/doi.org\/10.17998\/jlc.2025.06.13.","journal-title":"J Liver Cancer"},{"issue":"1","key":"1252_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.17998\/jlc.2024.12.02","volume":"25","author":"H Suzuki","year":"2025","unstructured":"Suzuki H, Mishra S, Paul S, Hoshida Y. Molecular and immune landscape of hepatocellular carcinoma for therapeutic development. J Liver Cancer. 2025;25(1):9\u201318. https:\/\/doi.org\/10.17998\/jlc.2024.12.02.","journal-title":"J Liver Cancer"},{"issue":"1","key":"1252_CR14","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3350\/cmh.2025.0792","volume":"32","author":"WS Lee","year":"2026","unstructured":"Lee WS, Woo S, Lee SH, Jo GH, Kim I, Kim H, et al. Integrative multi-omics profiling identifies infiltrative hepatocellular carcinoma as an immunotherapy-resistant subtype with distinct molecular features. Clin Mol Hepatol. 2026;32(1):258\u201375. https:\/\/doi.org\/10.3350\/cmh.2025.0792.","journal-title":"Clin Mol Hepatol"},{"issue":"24","key":"1252_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17243967","volume":"17","author":"JH Kim","year":"2025","unstructured":"Kim JH, Han JW, Cho HS, Jang JW, Tak KY, Sung PS. Prognostic significance of Glypican-3 expression in hepatocellular carcinoma treated with atezolizumab-bevacizumab. Cancers (Basel). 2025;17(24):3967. https:\/\/doi.org\/10.3390\/cancers17243967.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1252_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.17998\/jlc.2025.12.21","volume":"26","author":"SK Choi","year":"2026","unstructured":"Choi SK, Woo S, Chon HJ. Immune-related adverse events in hepatocellular carcinoma: organ-specific patterns and management approaches. J Liver Cancer. 2026;26(1):65\u201382. https:\/\/doi.org\/10.17998\/jlc.2025.12.21.","journal-title":"J Liver Cancer"},{"issue":"2","key":"1252_CR17","doi-asserted-by":"publisher","first-page":"262","DOI":"10.17998\/jlc.2023.07.17","volume":"23","author":"MMP Lee","year":"2023","unstructured":"Lee MMP, Chan LL, Chan SL. The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma. J Liver Cancer. 2023;23(2):262\u201371. https:\/\/doi.org\/10.17998\/jlc.2023.07.17.","journal-title":"J Liver Cancer"},{"issue":"1","key":"1252_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101630","volume":"8","author":"A Vogel","year":"2026","unstructured":"Vogel A, Saborowski A, Rimassa L, El-Khoueiry A. Navigating second-line therapy after immunotherapy in advanced HCC. JHEP Rep. 2026;8(1):101630. https:\/\/doi.org\/10.1016\/j.jhepr.2025.101630.","journal-title":"JHEP Rep"},{"issue":"2","key":"1252_CR19","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000514312","volume":"10","author":"M Kudo","year":"2021","unstructured":"Kudo M. Sequential therapy for hepatocellular carcinoma after failure of atezolizumab plus bevacizumab combination therapy. Liver Cancer (Basel). 2021;10(2):85\u201393. https:\/\/doi.org\/10.1159\/000514312.","journal-title":"Liver Cancer (Basel)"},{"issue":"3","key":"1252_CR20","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1159\/000534303","volume":"13","author":"SY Hwang","year":"2024","unstructured":"Hwang SY, Lee SL, Liu H, Lee SS. Second-line treatment after failure of immune checkpoint inhibitors in hepatocellular carcinoma: tyrosine kinase inhibitor, retrial of immunotherapy, or locoregional therapy? Liver Cancer (Basel). 2024;13(3):246\u201355. https:\/\/doi.org\/10.1159\/000534303.","journal-title":"Liver Cancer (Basel)"},{"issue":"2","key":"1252_CR21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000512781","volume":"10","author":"C Yoo","year":"2021","unstructured":"Yoo C, Kim JH, Ryu MH, Park SR, Lee D, Kim KM, et al. Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: a multinational multicenter retrospective study. Liver Cancer (Basel). 2021;10(2):107\u201314. https:\/\/doi.org\/10.1159\/000512781.","journal-title":"Liver Cancer (Basel)"},{"issue":"6","key":"1252_CR22","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1007\/s00432-022-04115-w","volume":"149","author":"S Armstrong","year":"2023","unstructured":"Armstrong S, Roy T, Singh B, Kulasekaran M, Shaukat F, Geng X, et al. TKIs beyond immunotherapy predict improved survival in advanced HCC. J Cancer Res Clin Oncol. 2023;149(6):2559\u201374. https:\/\/doi.org\/10.1007\/s00432-022-04115-w.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"1252_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1159\/000520278","volume":"11","author":"G Cabibbo","year":"2022","unstructured":"Cabibbo G, Reig M, Celsa C, Torres F, Battaglia S, Enea M, et al. First-line immune checkpoint inhibitor-based sequential therapies for advanced hepatocellular carcinoma: rationale for future trials. Liver Cancer. 2022;11(1):75\u201384. https:\/\/doi.org\/10.1159\/000520278.","journal-title":"Liver Cancer"},{"issue":"4","key":"1252_CR24","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1159\/000542285","volume":"14","author":"YJ Kim","year":"2025","unstructured":"Kim YJ, Merle P, Finn RS, Kudo M, Klumpen HJ, Lim HY, et al. Regorafenib for hepatocellular carcinoma in real-world practice (REFINE): a prospective, observational study. Liver Cancer. 2025;14(4):391\u2013407. https:\/\/doi.org\/10.1159\/000542285.","journal-title":"Liver Cancer"},{"issue":"7","key":"1252_CR25","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1002\/ijc.32964","volume":"147","author":"KY Tak","year":"2020","unstructured":"Tak KY, Nam HC, Choi JY, Yoon SK, Kim CW, Kim HY, et al. Effectiveness of sorafenib dose modifications on treatment outcome of hepatocellular carcinoma: analysis in real-life settings. Int J Cancer. 2020;147(7):1970\u20138. https:\/\/doi.org\/10.1002\/ijc.32964.","journal-title":"Int J Cancer"},{"issue":"10","key":"1252_CR26","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1093\/annonc\/mdv244","volume":"26","author":"B McLellan","year":"2015","unstructured":"McLellan B, Ciardiello F, Lacouture ME, Segaert S, Van Cutsem E. Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. Ann Oncol. 2015;26(10):2017\u201326. https:\/\/doi.org\/10.1093\/annonc\/mdv244.","journal-title":"Ann Oncol"},{"issue":"Suppl. 1","key":"1252_CR27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000481241","volume":"93","author":"C Ogawa","year":"2017","unstructured":"Ogawa C, Morita M, Omura A, Noda T, Kubo A, Matsunaka T, et al. Hand-foot syndrome and post-progression treatment are the good predictors of better survival in advanced hepatocellular carcinoma treated with sorafenib: a multicenter study. Oncology (Williston Park). 2017;93(Suppl. 1):113\u20139. https:\/\/doi.org\/10.1159\/000481241.","journal-title":"Oncology (Williston Park)"},{"issue":"7","key":"1252_CR28","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.kjms.2018.03.006","volume":"34","author":"WT Chang","year":"2018","unstructured":"Chang WT, Lu SN, Rau KM, Huang CS, Lee KT. Increased cumulative doses and appearance of hand-foot skin reaction prolonged progression free survival in sorafenib-treated advanced hepatocellular carcinoma patients. Kaohsiung J Med Sci. 2018;34(7):391\u20139. https:\/\/doi.org\/10.1016\/j.kjms.2018.03.006.","journal-title":"Kaohsiung J Med Sci"},{"issue":"2","key":"1252_CR29","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3350\/cmh.2025.0972","volume":"32","author":"B Tao","year":"2026","unstructured":"Tao B, Yi C, Zhang B, Geng Y, Gu Y, Sun R, et al. ERBB3 blockade sensitizes hepatocellular carcinoma to regorafenib after first-line tyrosine kinase inhibitor resistance by inhibiting HIF1A-ABCB1 signaling. Clin Mol Hepatol. 2026;32(2):787\u2013807. https:\/\/doi.org\/10.3350\/cmh.2025.0972.","journal-title":"Clin Mol Hepatol"}],"updated-by":[{"DOI":"10.1007\/s11523-026-01255-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000}}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01252-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01252-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01252-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:10:32Z","timestamp":1790925032000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01252-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1252"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01252-x","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"18 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11523-026-01255-8","URL":"https:\/\/doi.org\/10.1007\/s11523-026-01255-8","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kwon Yong Tak, Hee Sun Cho, Jaejun Lee, Kyeungmo Yang, Ahlim Lee, Ji Won Han, Soon Kyu Lee, Hyun Yang, Heechul Nam, Hee Yeon Kim, Sung Won Lee, Seok-Hwan Kim, Do Seon Song, Myeong Jun Song, Jung Hyun Kwon, U Im Chang, Soon Woo Nam, Chang Wook Kim, Jeong Won Jang, Si Hyun Bae, Hae Lim Lee, and Pil Soo Sung have no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflicts of interest\/competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Institutional Review Board of The Catholic University of Korea (IRB no.: KC22EASI0342).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent was waived by the IRB because of the retrospective nature of the study and the use of anonymized clinical data.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets are not publicly available because of patient privacy and institutional review board restrictions but may be available from the corresponding author on reasonable request, subject to institutional approval.","order":5,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The analysis code is available from the corresponding author on reasonable request.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}